Introduction
Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor-superfamily that has been identified in a broad range of cells.
1 -4 Apart from the placenta, where GDF-15 concentrations are physiologically high, 5 circulating GDF-15 levels generally increase with age, 6 with median levels of circulating GDF-15 in apparently healthy elderly individuals being in the range of 762 ng/L. 7 In pathology, GDF-15 concentrations appear to increase as a result of a number of stimuli, including inflammation, oxidative stress, and tissue hypoxia or injury, 4 but the biological significance of this increase remains unclear due to a lack of knowledge of its receptor and the signalling pathways that drive its actions. Recently, GDF-15 has been shown to bind the GDNF family receptor -like (GFRAL) in animal models of obesity, suggesting a potential role in the regulation of metabolism. 8 Circulating GDF-15 concentrations have been shown to increase significantly in a large number of pathological conditions, including renal dysfunction, diabetes, and sepsis. 9 -11 GDF-15 levels can also increase as a result of production in other tissues, particularly in certain cancerous cells. 2, 3 In animal models of heart failure (HF) and acute myocardial infarction, cardiomyocytes can be stimulated to produce GDF-15, and GDF-15 has been found to be produced in atherosclerotic plaques. 12, 13 However, in patients with chronic non-ischaemic cardiomyopathy undergoing left ventricular assist device therapy, cardiomyocytes do not produce GDF-15, even though circulating GDF-15 levels are high.
14,15
Circulating concentrations of GDF-15 have been shown to be increased in chronic HF with reduced ejection fraction (HFrEF) and to be predictive of cardiovascular (CV) outcomes. 1, 7, 16 However, although GDF-15 values decrease transiently with serelaxin in patients with acute HF, 17 interventions that change the course of chronic HFrEF do not yield changes in GDF-15.
18,19
In the Prospective comparison of ARNI with ACEi to Determine the Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan significantly improved outcomes in patients with HFrEF. 20 Biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP), 21 high-sensitivity troponin T (hs-TnT) 22 and high-sensitivity C-reactive protein (hs-CRP) 23 have been shown to be predictive of outcomes in patients with HFrEF, and in PARADIGM-HF, sacubitril/valsartan reduced both NT-proBNP and hs-TnT more than enalapril. 21, 22 In the current analysis of the PARADIGM-HF trial, we sought to describe (i) changes in circulating GDF-15 levels as a result of assigned treatment; and (ii) the association of baseline circulating GDF-15 levels and changes in GDF-15 levels after 1 and 8 months of therapy and subsequent outcomes.
Methods
The design and primary results of the PARADIGM-HF trial have been described elsewhere. 24 Patients with chronic HF, New York Heart Association (NYHA) class II-IV symptoms, elevated plasma levels of natriuretic peptides, and systolic left ventricular dysfunction (left ventricular ejection fraction ≤ 40%) were eligible for randomization in PARADIGM-HF. The primary outcome was a composite of death from CV causes or hospitalization for HF. Causes of death (either CV or non-CV) as well as CV hospitalizations were adjudicated by an endpoint committee that was blinded to treatment assignment. The timing and process for obtaining, storing and processing samples have been described elsewhere. 21, 22 
GDF-15
Serum GDF-15 measurements were obtained at baseline (n = 1935), 1 month (n = 1935) and 8 months (n = 1695) after randomization, using the Quantikine GDF-15 ELISA assay (R&D Systems, MN, USA; lower limit of detection of 10 ng/L, reporting range of 14.1-12 000, coefficient of variation ≤ 3%). Samples were stored at the study sites at -20 ∘ C or lower, followed by storage at -80 ∘ C at the central laboratory. According to what has previously been published with regard to GDF-15 reference change values in patients with chronic HF, we considered in this analysis a 20% increase in values as relevant. 25 
Statistical analysis
Baseline characteristics were summarized for patients with and without available baseline GDF-15 values using counts and percentages for categorical variables and mean ±SD or median [interquartile range (IQR)] for continuous variables. The two groups were compared using Chi-squared tests, t-tests, and Wilcoxon rank-sum tests, as appropriate. For patients with paired GDF-15 at baseline and 1-month and/or 8-month follow-up visits, median (IQR) GDF-15 levels and changes from baseline are reported at each time point, with the median between-treatment difference at each time point estimated via quantile regression, adjusted for baseline GDF-15. Multivariate associations between baseline characteristics and log-transformed baseline GDF-15 values were explored using a forward stepwise selection procedure with P-value threshold of 0.01. The unadjusted and adjusted relationships between baseline GDF-15 and clinical outcomes were assessed using Cox proportional hazards models with log-transformed GDF-15 and with adjusted models including randomized treatment and all baseline characteristics listed in Table 1 , with the exception of race and NT-proBNP due to high correlation with geographic region and NT-proBNP, respectively. Non-CV outcomes could not be fully adjusted as potentially important non-CV determinants of outcomes were not available to be included in the adjusted analysis. Harrell's C-statistics for models with and without GDF-15 were estimated, and interactions between GDF-15 and randomized treatment were tested. Adjusted incidence rates were also modelled as a function of baseline GDF-15 separately in each group using restricted cubic splines with 3 knots, and potential treatment interactions were tested via likelihood ratio tests. Similar analyses of post-baseline changes in GDF-15 were performed via landmark analysis with adjustment for baseline GDF-15. Continuous net reclassification index was calculated at follow-up times of 1.5, 2.0, and 2.5 years to quantify the added value of baseline and changes in GDF-15 relative to the previously described adjusted model. All analyses were conducted using STATA version 14 (College Station, TX, USA) and P-values < 0.05 were considered to be statistically significant. ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; CRT, cardiac resynchronization therapy; GDF-15, growth differentiation factor-15; hs-TnT, high-sensitivity troponin T; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure.
male, more frequently white, more frequently from Europe or North America, had more diabetes, atrial fibrillation or prior myocardial infarction, a higher creatinine, and more frequently had an implantable cardioverter defibrillator or cardiac resynchronization therapy ( Table 1) . They less frequently received a mineralocorticoid antagonist, and had a lower NT-proBNP and hs-TnT.
As compared with patients in whom GDF-15 was not measured, . . patients in the GDF-15 cohort had fewer primary events, fewer HF deaths, fewer CV deaths, fewer non-HF CV deaths, and a lower all-cause mortality, and they had more non-CV hospitalizations and non-CV death (online supplementary Table S1 ). The only notable difference in the characteristics of patients randomized to enalapril or sacubitril/valsartan in the GDF-15 cohort was that more patients in the enalapril group were taking a mineralocorticoid receptor antagonist (online supplementary  Table S2 ). Patients taking sacubitril/valsartan less frequently had the primary composite outcome and hospitalization for HF than patients taking enalapril (online supplementary Table S3 ).
GDF-15 values and their determinants at baseline
Median baseline GDF-15 values were elevated above mean values in apparently healthy populations [762 ng/L (600-959)] 7 and were similar in both the sacubitril/valsartan and enalapril groups [1626 ng/L (1159-2398) and 1690 ng/L (1175-2451), respectively]. In multivariable analyses, baseline values of GDF-15 were most closely associated with diabetes, age, creatinine, hs-TnT, NT-proBNP and NYHA class III/IV (online supplementary Table  S4 , adjusted R 2 = 0.3857). Other determinants included geographic region and diuretic use.
Baseline GDF-15 values and outcomes
The risk of the primary outcome increased linearly with increasing baseline GDF-15 values (Figure 1 ). Each 20% increment in baseline GDF-15 concentration (log-transformed) was associated with an increased risk of mortality, the primary endpoint of the combination of CV death and hospitalization for HF, hospitalization for HF, HF death, CV death, CV non-HF death, and CV non-HF hospitalization (unadjusted, all P < 0.001) ( Table 2 ). The exceptions were bleeding events whose hazard ratio did not reach statistical significance after adjustment, and stroke and thromboembolic events that had no numerical increase in hazard ratio with GDF-15. After adjustment, there was no interaction with treatment ( Table 2) . Each 20% increment in baseline GDF-15 concentration (log-transformed) was also associated with non-CV death and non-CV hospitalization (unadjusted, P < 0.001) ( Table 2) . Fully adjusted associations between GDF-15 and both non-CV death and non-CV hospitalization could not be performed due to missing potentially important non-CV baseline covariates.
The C-statistic for unadjusted baseline GDF-15 values ranged from 0.56 for CV non-HF hospitalization, to 0.75 for HF death ( Table 2 ). When GDF-15 values were added to a model for outcomes comprised of clinical, biochemical and biomarker (NT-proBNP and hs-TnT) variables, they had little impact on the C-statistic (0.00-0.02). However, the addition of baseline or change in GDF-15 to the model for predicting outcomes slightly, but significantly improved the net reclassification index for the primary outcome and for total mortality at 1.5, 2.0 and 2.5 years of follow-up (8.6 to 12.8% of patients, P-value from 0.06 to < 0.001) as compared with the model without baseline GDF-15 values (online supplementary Table S5 ).
Relationship between baseline GDF-15, NT-proBNP and hs-TnT and outcomes
There was a significant correlation between baseline GDF-15 values and NT-proBNP, (R 2 = 0.24, P < 0.001) and hs-TnT (R 2 = 0.43, p < 0.001) (online supplementary Figure S1 ). All three biomarkers were separately associated with prognosis (P < 0.001 for NT-proBNP, hs-TnT and GDF-15 for the primary outcome after . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . adjustment). However, after adjustment, there were no significant interactions between any of these biomarkers (NT-proBNP, hs-TnT and GDF-15) with respect to the composite primary outcome of CV death or hospitalization for HF (P = 0.13).
Changes in GDF-15 over time and impact of change in GDF-15 at 1 and 8 months and outcomes
The change in GDF-15 values from baseline to 1 and 8 months of follow-up were not different between enalapril and sacubitril/valsartan groups (all P ≥ 0.1) (online supplementary Table S6 ). No significant interaction was found between GDF-15 values, risk, and therapy, although the difference in the curves of the relationship between GDF-15 vs. HF hospitalization for sacubitril/valsartan and enalapril approached significance, events being less frequent with sacubitril/valsartan than enalapril for any GDF-15 value (Figure 2) Change in GDF-15 values at 1 month and 8 months was also associated (before and after adjustment) with mortality and all CV outcomes, including the primary endpoint, hospitalization for HF, HF death, CV death, CV non-HF death (borderline significant), and CV non-HF hospitalization when assessed as a 20% change in GDF-15 (log-transformed) ( Table 3 and online supplementary  Table S7 ). The exceptions were stroke and thromboembolic events whose hazard ratio did not reach statistical significance, perhaps due to low numbers; and bleeding events that had no numerical increase in hazard ratio with GDF-15. A treatment interaction for HF death and a borderline interaction for CV death were found with a 20% increase in GDF at 1 but not 8 months. No other significant interaction of study therapy on change in GDF-15 values and outcomes was found ( Table 3 and online supplementary  Table S7 ). No apparent difference in the pattern of the relationship between change in GDF-15 at 1 and 8 months and outcomes in patients on enalapril and sacubitril/valsartan was found ( Figure 3 and online supplementary Figure S2 ). Change in GDF-15 values at 1 month and 8 months was also associated with non-CV hospitalizations and non-CV death (unadjusted, P < 0.001) ( Table 3) . Fully adjusted associations between GDF-15 and both non-CV death and non-CV hospitalization could not be performed due to missing potentially important non-CV baseline covariates.
Again, adding change in GDF-15 values at 1 month to a predictive model for outcomes that included baseline GDF-15 values in addition to clinical, biochemical and biomarker variables significantly improved the net classification index for both the primary outcome and total mortality at 1.5, 2.0 and 2.5 years (13.3 to 18.3% of patients, P-value from 0.007 to < 0.001) (online supplementary  Table S5 ).
Discussion
This study confirms that GDF-15 values are increased in chronic HFrEF compared to mean values recorded in apparently healthy populations, 6, 7, 26, 27 and that, in this setting, the determinants of circulating GDF-15 appear to be mostly influenced by the presence of diabetes, hs-TnT, and NYHA class III/IV (adjusted R 2 = 0.3857). This study confirms that baseline GDF-15 values and changes over time are significantly associated with mortality and adverse CV outcomes. Accordingly, GDF-15 levels did not change with either sacubitril/valsartan or enalapril, despite differential effects of these drugs on cardiac-specific biomarkers such as NT-proBNP and hs-TnT and on mortality and CV outcomes. The addition of GDF-15 to a comprehensive model for predicting outcomes reclassifies the risk of a small number of patients with chronic ambulatory HFrEF for the primary outcome of CV death and HF hospitalizations and for total mortality.
Determinants of GDF-15 in heart failure with reduced ejection fraction and response to therapy
In PARADIGM-HF, as in previous trials in patients with chronic HF, 1, 18, 19 circulating GDF-15 values were on average more than twice normal, and in this setting of HFrEF, the major determinants of GDF-15 values were diabetes, advanced age, abnormal renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . function, NT-proBNP, hs-TnT, and NYHA class III/IV (adjusted R 2 = 0.3857). As in previous studies of patients with chronic ambulatory HFrEF, in PARADIGM-HF, there was a lack of response of GDF-15 to an intervention that improved CV outcomes. In the Valsartan Heart Failure Trial (Val-HeFT), 18 valsartan did not modify circulating levels of GDF-15 although it significantly improved CV outcomes; nor did cardiac resynchronization therapy modify circulating levels of GDF-15 in another study of patients with HFrEF, 19 despite improving symptoms and ventricular function. However, in severely ill patients with acute or end-stage HF, serelaxin, 17 or left ventricular assist device therapy 14,15 is accompanied by short-term decreases in circulating GDF-15 levels. As such, GDF-15 is likely to represent an integrated biomarker of multiple co-morbidities rather than a specific reflection of CV health, and one could hypothesize that GDF-15 is found to be linked to CV risk when this biomarker is studied in populations whose mortality is largely related to CV events.
Relationship between GDF-15 and outcomes
In the controlled trial investigating outcomes of exercise training (HF-ACTION) after having adjusted for clinical variables, hs-TnT and NT-proBNP, baseline GDF-15 was only predictive of total mortality, and not of either CV death or the combination of CV death and HF hospitalizations.
1 In PARADIGM-HF, baseline and change in GDF-15 were not only associated with total mortality, but also with both CV death and hospitalization, and with HF death and hospitalization. Unadjusted baseline and change in GDF-15 were also associated with non-CV hospitalizations and non-CV death; however, due to potentially important missing non-CV covariates, fully adjusted associations between GDF-15 and non-CV outcomes could not be performed such that these unadjusted results need to be interpreted with caution.
The impact of including GDF-15 to a predictive model of outcomes does not add much in terms of risk prediction as it had little impact on C-statistic for both total mortality and CV outcomes. The impact of adding GDF-15 to the net reclassification of a patients' risk for the primary outcome of CV mortality or HF hospitalization, or for total mortality was small, although statistically significant.
We found GDF-15 to be predictive of poor outcomes independent of other biomarkers (NT-proBNP and hs-TnT). In patients with chronic coronary artery disease, in a model that included NT-proBNP, hs-CRP and hs-TnT, baseline and a 20% increase or decrease in GDF-15 values at 12 months were associated with both subsequent CV events and overall mortality. 28 Inclusion of GDF-15 in that study rendered hs-CRP of marginal significance in predicting outcomes suggesting a strong association between GDF-15 levels and outcomes in that setting. 28 In patients with non-ST elevation myocardial infarction, the inclusion of GDF-15 values improved the predictive value of the Global Registry of Acute Coronary Events (GRACE) score, and reduced the predictive value of other biomarkers post-myocardial infarction. 29 GDF-15 has also been shown to be independently associated with outcomes in patients with cancer, 2 
Limitations
In this analysis, patients in the GDF-15 cohort differed significantly from that of those not in the GDF-15 cohort, limiting the ability of extrapolating the results of this cohort to the general population with HFrEF. This having been said, the consistency of the results of these analyses with that of other trials is reassuring. We used a cut-off of a 20% increase in GDF-15 levels to assess the impact of changes in GDF-15 values and, due to the linear association of risk with both baseline and change in GDF-15 values, we chose not to assess the impact of increasing above or below a specific GDF-15 value. Due to missing potentially important non-CV covariates, the association between GDF-15 and non-CV events could not be fully adjusted such that unadjusted values relating GDF-15 values and non-CV events need to be interpreted with caution.
Conclusions
In patients with chronic stable HFrEF, baseline and changes in GDF-15 values are not modified by sacubitril/valsartan and are independently associated with poor CV outcomes and survival. Additional studies are needed to define the role of routine GDF-15 in the diagnosis and management of chronic HFrEF patients.
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